Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study.
Troels ThimLars JakobsenRebekka Vibjerg JensenNicolaj StøttrupAshkan EftekhariErik Lerkevang GroveSanne Bøjet LarsenJacob Thorsted SørensenSteen CarstensenSahar AmiriKarsten Tange VeienEvald Høj ChristiansenChristian Juhl TerkelsenMichael MaengSteen Dalby KristensenPublished in: Cardiology research and practice (2023)
= 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.
Keyphrases
- percutaneous coronary intervention
- liver failure
- respiratory failure
- st segment elevation myocardial infarction
- patients undergoing
- st elevation myocardial infarction
- acute myocardial infarction
- drug induced
- coronary artery disease
- acute coronary syndrome
- aortic dissection
- early stage
- heart failure
- atrial fibrillation
- hepatitis b virus
- pulmonary embolism
- intensive care unit
- climate change
- risk assessment
- left ventricular
- mechanical ventilation